Quidel Corp. (QDEL)

65.42
3.00 4.30
NASDAQ : Health Technology
Prev Close 68.38
Open 68.14
Day Low/High 65.28 / 68.33
52 Wk Low/High 26.27 / 70.28
Volume 74.84K
Avg Volume 359.60K
Exchange NASDAQ
Shares Outstanding 37.46M
Market Cap 2.56B
EPS -0.20
P/E Ratio 341.35
Div & Yield N.A. (N.A)

Latest News

Quidel To Present At UBS Global Healthcare Conference

Quidel To Present At UBS Global Healthcare Conference

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the UBS Global Healthcare Conference at the Grand Hyatt New...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAXN, GBLI, HAE, NWN, OXY, QDEL, TTI, ZBRA Downgrades: AC, ACM, ARMK, COKE, EDN, EPR, IT, KEYW, MG, MNTA, TEN, TRIP Initiations: DSKE, SNAP Read on to get TheStreet Quant Ratings' detailed report:

Quidel Reports First Quarter 2018 Financial Results

Quidel Reports First Quarter 2018 Financial Results

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first quarter ended March 31, 2018.

QDEL Crosses Above Average Analyst Target

In recent trading, shares of Quidel Corp. have crossed above the average analyst 12-month target price of $56.00, changing hands for $56.70/share.

Quidel To Hold First Quarter 2018 Financial Results Conference Call On May 8, 2018

Quidel To Hold First Quarter 2018 Financial Results Conference Call On May 8, 2018

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report first quarter 2018 financial results after market close on Tuesday, May 8, 2018.

Quidel To Host 2018 Analyst And Investor Day In Chicago

Quidel To Host 2018 Analyst And Investor Day In Chicago

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will host its 2018 Quidel Analyst and Investor Day at the Hyatt Regency...

Quidel Announces Private Exchange Transactions

Quidel Announces Private Exchange Transactions

Quidel Corporation (NASDAQ: QDEL) ("Quidel"), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that it has entered into separate, privately...

Quidel Receives FDA Clearance For Its Point-of-Care Sofia® Lyme Fluorescent Immunoassay For Use With Sofia® 2 Instrument

Quidel Receives FDA Clearance For Its Point-of-Care Sofia® Lyme Fluorescent Immunoassay For Use With Sofia® 2 Instrument

Quidel Corporation (NASDAQ: QDEL) ("Quidel"), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from...

Quidel To Present At Upcoming Conferences

Quidel To Present At Upcoming Conferences

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the following upcoming...

Quidel Reports Fourth Quarter And Full Year 2017 Financial Results

Quidel Reports Fourth Quarter And Full Year 2017 Financial Results

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and year ended...

Quidel Receives 510(k) Clearance For QuickVue® Influenza A+B Test, Assay Meets FDA's Class II RIDT Requirements

Quidel Receives 510(k) Clearance For QuickVue® Influenza A+B Test, Assay Meets FDA's Class II RIDT Requirements

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United...

Quidel To Hold Fourth Quarter And Full Year 2017 Financial Results Conference Call On February 21, 2018

Quidel To Hold Fourth Quarter And Full Year 2017 Financial Results Conference Call On February 21, 2018

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fourth quarter and full year 2017 financial results after...

Quidel Completes Sale Leaseback Of Summers Ridge Property For $148.65 Million

Quidel Completes Sale Leaseback Of Summers Ridge Property For $148.65 Million

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has completed the sale leaseback transaction for...

Quidel Receives FDA Clearance And CLIA Waiver For Its Point-of-Care Sofia® 2 Instrument For Use With Sofia Strep A+ Assay

Quidel Receives FDA Clearance And CLIA Waiver For Its Point-of-Care Sofia® 2 Instrument For Use With Sofia Strep A+ Assay

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today it has received 510(k) clearance and Clinical Laboratory...

Quidel Receives FDA Clearance For Its New Solana® Molecular Assay For The Detection Of Group B Streptococcal Infections

Quidel Receives FDA Clearance For Its New Solana® Molecular Assay For The Detection Of Group B Streptococcal Infections

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today it has received 510(k) clearance from the United States...

Quidel To Present At 36th Annual J.P. Morgan Healthcare Conference

Quidel To Present At 36th Annual J.P. Morgan Healthcare Conference

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it will present at the 36 th Annual J.

First Week of February 2018 Options Trading For Quidel (QDEL)

First Week of February 2018 Options Trading For Quidel (QDEL)

Investors in Quidel Corp. saw new options begin trading this week, for the February 2018 expiration.

Quidel Files Form 8-K/A, Reports Historical And Pro Forma Financial Information For Acquired Triage Assets And Combined Quidel And Triage Businesses

Quidel Files Form 8-K/A, Reports Historical And Pro Forma Financial Information For Acquired Triage Assets And Combined Quidel And Triage Businesses

Quidel Corporation (NASDAQ: QDEL) ("Quidel", "the Company"), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today filed the Company's required report on...

Quidel Announces Timing Of Filing Of Form 8-K/A To Report Historical And Pro Forma Financial Information For Acquired Triage Assets And Combined Quidel And Triage Businesses

Quidel Announces Timing Of Filing Of Form 8-K/A To Report Historical And Pro Forma Financial Information For Acquired Triage Assets And Combined Quidel And Triage Businesses

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that it plans to file its required report on Form 8-K/A with...

Short Interest Drops 10.2% For QDEL

Short Interest Drops 10.2% For QDEL

The most recent short interest data has been released for the 11/15/2017 settlement date, which shows a 411,389 share decrease in total short interest for Quidel Corp. , to 3,632,267, a decrease of 10.17% since 10/31/2017.

Quidel Confident In Legal Strength And Validity Of Supply Agreement With Beckman Coulter To Sell BNP Assay Assets

Quidel Confident In Legal Strength And Validity Of Supply Agreement With Beckman Coulter To Sell BNP Assay Assets

Quidel Corporation (NASDAQ: QDEL) ("Quidel"), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, acknowledged Beckman Coulter ("Beckman") plans to pursue...

Quidel To Present At The 29th Annual Piper Jaffray Healthcare Conference

Quidel To Present At The 29th Annual Piper Jaffray Healthcare Conference

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the 29 th Annual Piper Jaffray...

Quidel Reports Third Quarter 2017 Financial Results

Quidel Reports Third Quarter 2017 Financial Results

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the third quarter ended...

Quidel Receives FDA Clearance For Its Point-of-Care Sofia® Lyme FIA

Quidel Receives FDA Clearance For Its Point-of-Care Sofia® Lyme FIA

Quidel Corporation (NASDAQ: QDEL) ("Quidel"), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from...

Quidel Receives FDA Clearance For Its Solana® RSV + HMPV Assay

Quidel Receives FDA Clearance For Its Solana® RSV + HMPV Assay

Quidel Corporation (NASDAQ: QDEL) ("Quidel"), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received clearance from the...

Quidel To Hold Third Quarter 2017 Financial Results Conference Call On November 1, 2017

Quidel To Hold Third Quarter 2017 Financial Results Conference Call On November 1, 2017

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report third quarter 2017 financial results after market close on...

Quidel Announces Closing Of Acquisition Of Alere Triage® Assets Creating An Expanded Portfolio Of Rapid Diagnostic Capabilities In Critical Care Settings

Quidel Announces Closing Of Acquisition Of Alere Triage® Assets Creating An Expanded Portfolio Of Rapid Diagnostic Capabilities In Critical Care Settings

Quidel Corporation (NASDAQ: QDEL) ("Quidel"), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that it has closed its previously announced...

Quidel Announces Early Termination Of The Hart-Scott-Rodino Waiting Period For Its Pending Acquisition Of Alere's Triage® B-type Naturietic Peptide (BNP) Assay Business Run On Beckman Coulter Analyzers

Quidel Announces Early Termination Of The Hart-Scott-Rodino Waiting Period For Its Pending Acquisition Of Alere's Triage® B-type Naturietic Peptide (BNP) Assay Business Run On Beckman Coulter Analyzers

Quidel Corporation (NASDAQ: QDEL) ("Quidel"), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that it has received notice from the Federal Trade...

TheStreet Quant Rating: B (Buy)